Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop)

Teri A. Manolio, Kenneth L. Baughman, Richard Rodeheffer, Thomas A. Pearson, J. David Bristow, Virginia V. Michels, Walter H. Abelmann, William R. Harlan

Research output: Contribution to journalArticle

336 Citations (Scopus)

Abstract

Idiopathic dilated cardiomyopathy (IDC) is the primary indication for cardiac transplantation, with associated costs of approximately $177 million per year. Recognizing the economic implications of IDC, the increasing incidence, and the limited information on pathogenesis and prognosis, the National Heart, Lung, and Blood Institute convened a workshop on the Prevalence and Etiology of Idiopathic Dilated Cardiomyopathy on June 13 to 14, 1991. The difficulties of studying the disease were reviewed, including its relatively low prevalence, its potentially pluricausal nature, and the fact that it is often a diagnosis of exclusion. Still, it presents significant challenges to the cardiovascular scientific community, since the mechanism of myocardial damage and related etiologic and prognostic factors are virtually unknown. The development of more reliable measures of immune-mediated damage and noninvasive measures of impaired cardiac function present new research opportunities in this disorder. Standardized diagnostic criteria for use in observational and interventional trials were developed, and priorities for future research were proposed. Population-based registries and nested case-control studies, where feasible, are appropriate study designs for tracking incidence and prevalence, and for identifying risk factors, respectively. Interventional studies should focus on secondary prevention, through modifying immunemediated damage in clinically evident dilated cardiomyopathy, and through prevention of sudden death in patients with the disorder. Primary prevention trials must await the identification of modifiable risk factors and of appropriate and effective interventions.

Original languageEnglish (US)
Pages (from-to)1458-1466
Number of pages9
JournalThe American Journal of Cardiology
Volume69
Issue number17
DOIs
StatePublished - Jun 1 1992

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Dilated Cardiomyopathy
Education
Incidence
Heart Transplantation
Primary Prevention
Sudden Death
Secondary Prevention
Registries
Case-Control Studies
Economics
Costs and Cost Analysis
Research
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Manolio, T. A., Baughman, K. L., Rodeheffer, R., Pearson, T. A., Bristow, J. D., Michels, V. V., ... Harlan, W. R. (1992). Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop). The American Journal of Cardiology, 69(17), 1458-1466. https://doi.org/10.1016/0002-9149(92)90901-A

Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop). / Manolio, Teri A.; Baughman, Kenneth L.; Rodeheffer, Richard; Pearson, Thomas A.; Bristow, J. David; Michels, Virginia V.; Abelmann, Walter H.; Harlan, William R.

In: The American Journal of Cardiology, Vol. 69, No. 17, 01.06.1992, p. 1458-1466.

Research output: Contribution to journalArticle

Manolio, TA, Baughman, KL, Rodeheffer, R, Pearson, TA, Bristow, JD, Michels, VV, Abelmann, WH & Harlan, WR 1992, 'Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop)', The American Journal of Cardiology, vol. 69, no. 17, pp. 1458-1466. https://doi.org/10.1016/0002-9149(92)90901-A
Manolio, Teri A. ; Baughman, Kenneth L. ; Rodeheffer, Richard ; Pearson, Thomas A. ; Bristow, J. David ; Michels, Virginia V. ; Abelmann, Walter H. ; Harlan, William R. / Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop). In: The American Journal of Cardiology. 1992 ; Vol. 69, No. 17. pp. 1458-1466.
@article{f7fe1c9f69cf4d98b9d0bac7fdafc558,
title = "Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop)",
abstract = "Idiopathic dilated cardiomyopathy (IDC) is the primary indication for cardiac transplantation, with associated costs of approximately $177 million per year. Recognizing the economic implications of IDC, the increasing incidence, and the limited information on pathogenesis and prognosis, the National Heart, Lung, and Blood Institute convened a workshop on the Prevalence and Etiology of Idiopathic Dilated Cardiomyopathy on June 13 to 14, 1991. The difficulties of studying the disease were reviewed, including its relatively low prevalence, its potentially pluricausal nature, and the fact that it is often a diagnosis of exclusion. Still, it presents significant challenges to the cardiovascular scientific community, since the mechanism of myocardial damage and related etiologic and prognostic factors are virtually unknown. The development of more reliable measures of immune-mediated damage and noninvasive measures of impaired cardiac function present new research opportunities in this disorder. Standardized diagnostic criteria for use in observational and interventional trials were developed, and priorities for future research were proposed. Population-based registries and nested case-control studies, where feasible, are appropriate study designs for tracking incidence and prevalence, and for identifying risk factors, respectively. Interventional studies should focus on secondary prevention, through modifying immunemediated damage in clinically evident dilated cardiomyopathy, and through prevention of sudden death in patients with the disorder. Primary prevention trials must await the identification of modifiable risk factors and of appropriate and effective interventions.",
author = "Manolio, {Teri A.} and Baughman, {Kenneth L.} and Richard Rodeheffer and Pearson, {Thomas A.} and Bristow, {J. David} and Michels, {Virginia V.} and Abelmann, {Walter H.} and Harlan, {William R.}",
year = "1992",
month = "6",
day = "1",
doi = "10.1016/0002-9149(92)90901-A",
language = "English (US)",
volume = "69",
pages = "1458--1466",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "17",

}

TY - JOUR

T1 - Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop)

AU - Manolio, Teri A.

AU - Baughman, Kenneth L.

AU - Rodeheffer, Richard

AU - Pearson, Thomas A.

AU - Bristow, J. David

AU - Michels, Virginia V.

AU - Abelmann, Walter H.

AU - Harlan, William R.

PY - 1992/6/1

Y1 - 1992/6/1

N2 - Idiopathic dilated cardiomyopathy (IDC) is the primary indication for cardiac transplantation, with associated costs of approximately $177 million per year. Recognizing the economic implications of IDC, the increasing incidence, and the limited information on pathogenesis and prognosis, the National Heart, Lung, and Blood Institute convened a workshop on the Prevalence and Etiology of Idiopathic Dilated Cardiomyopathy on June 13 to 14, 1991. The difficulties of studying the disease were reviewed, including its relatively low prevalence, its potentially pluricausal nature, and the fact that it is often a diagnosis of exclusion. Still, it presents significant challenges to the cardiovascular scientific community, since the mechanism of myocardial damage and related etiologic and prognostic factors are virtually unknown. The development of more reliable measures of immune-mediated damage and noninvasive measures of impaired cardiac function present new research opportunities in this disorder. Standardized diagnostic criteria for use in observational and interventional trials were developed, and priorities for future research were proposed. Population-based registries and nested case-control studies, where feasible, are appropriate study designs for tracking incidence and prevalence, and for identifying risk factors, respectively. Interventional studies should focus on secondary prevention, through modifying immunemediated damage in clinically evident dilated cardiomyopathy, and through prevention of sudden death in patients with the disorder. Primary prevention trials must await the identification of modifiable risk factors and of appropriate and effective interventions.

AB - Idiopathic dilated cardiomyopathy (IDC) is the primary indication for cardiac transplantation, with associated costs of approximately $177 million per year. Recognizing the economic implications of IDC, the increasing incidence, and the limited information on pathogenesis and prognosis, the National Heart, Lung, and Blood Institute convened a workshop on the Prevalence and Etiology of Idiopathic Dilated Cardiomyopathy on June 13 to 14, 1991. The difficulties of studying the disease were reviewed, including its relatively low prevalence, its potentially pluricausal nature, and the fact that it is often a diagnosis of exclusion. Still, it presents significant challenges to the cardiovascular scientific community, since the mechanism of myocardial damage and related etiologic and prognostic factors are virtually unknown. The development of more reliable measures of immune-mediated damage and noninvasive measures of impaired cardiac function present new research opportunities in this disorder. Standardized diagnostic criteria for use in observational and interventional trials were developed, and priorities for future research were proposed. Population-based registries and nested case-control studies, where feasible, are appropriate study designs for tracking incidence and prevalence, and for identifying risk factors, respectively. Interventional studies should focus on secondary prevention, through modifying immunemediated damage in clinically evident dilated cardiomyopathy, and through prevention of sudden death in patients with the disorder. Primary prevention trials must await the identification of modifiable risk factors and of appropriate and effective interventions.

UR - http://www.scopus.com/inward/record.url?scp=0026629099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026629099&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(92)90901-A

DO - 10.1016/0002-9149(92)90901-A

M3 - Article

C2 - 1590237

AN - SCOPUS:0026629099

VL - 69

SP - 1458

EP - 1466

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 17

ER -